T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival

References

• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–14. doi:10.1056/NEJMoa055531.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon J-P, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre J-M, Saint-Aubert B, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721. doi:10.1200/JCO.2010.33.0597.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp H-G, Mayer F, Haag GM, Luley K, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. doi:10.1016/S0140-6736(18)32557-1.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214–234. doi:10.1038/modpathol.2017.156.
   PubMed Web of Science ®Google Scholar
• Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99(10):1704–1711. doi:10.1038/sj.bjc.6604738.
   PubMed Web of Science ®Google Scholar
• Stein AV, Dislich B, Blank A, Guldener L, Kroll D, Seiler CA, Langer R. High intratumoural but not peritumoural inflammatory host response is associated with better prognosis in primary resected oesophageal adenocarcinomas. Pathology. 2017;49(1):30–37. doi:10.1016/j.pathol.2016.10.005.
   PubMed Web of Science ®Google Scholar
• Lee JS, Won HS, Sun S, Hong JH, Ko YH. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a systematic review and meta-analysis. Medicine. 2018;97(32):e11769. doi:10.1097/MD.0000000000011769.
   PubMed Web of Science ®Google Scholar
• Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, Micke P, Nodin B, Leandersson K, Jirström K, et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget. 2017;8(42):72108–72126. doi:10.18632/oncotarget.19437.
   PubMedGoogle Scholar
• Shen Z, Zhou S, Wang Y, Li R-L, Zhong C, Liang C, Sun Y. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol. 2010;136(10):1585–1595. doi:10.1007/s00432-010-0816-9.
   PubMed Web of Science ®Google Scholar
• Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, Li Q, Chen M, Wang L. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 2014;96(3):284–291. doi:10.1016/j.yexmp.2014.03.005.
   PubMed Web of Science ®Google Scholar
• Hennequin A, Derangere V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016;5(2):e1054598. doi:10.1080/2162402X.2015.1054598.
   PubMed Web of Science ®Google Scholar
• Ni Z, Xing D, Zhang T, Ding N, Xiang D, Zhao Z, Qu J, Hu C, Shen X, Xue X, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunol Res. 2021;69(1):43–52. doi:10.1007/s12026-020-09167-z.
   PubMed Web of Science ®Google Scholar
• Fristedt R, Borg D, Hedner C, Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol. 2016;7(6):848–859. doi:10.21037/jgo.2016.11.07.
   PubMed Web of Science ®Google Scholar
• Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol. 2006;7(4):344–353. doi:10.1038/ni1330.
   PubMed Web of Science ®Google Scholar
• Schlosser HA, Thelen M, Lechner A, Wennhold K, Garcia-Marquez MA, Rothschild SI, Staib E, Zander T, Beutner D, Gathof B, et al. B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. Oncoimmunology. 2019;8(1):e1512458. doi:10.1080/2162402X.2018.1512458.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112(11):1782–1790. doi:10.1038/bjc.2015.145.
   PubMed Web of Science ®Google Scholar
• Sakimura C, Tanaka H, Okuno T, Hiramatsu S, Muguruma K, Hirakawa K, Wanibuchi H, Ohira M. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. J Surg Res. 2017;215:74–82. doi:10.1016/j.jss.2017.03.033.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang D, He W, Chen T, Yan Z, Gao X, Chen L, Zheng X, Xu B, Lu B, et al. CD8+ T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. Oncol Lett. 2020;20(3):2655–2664. doi:10.3892/ol.2020.11828.
   PubMed Web of Science ®Google Scholar
• Kelly RJ LBA9_PR - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the CheckMate 577 study; 2020 Sep 21. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020.
   Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges J-P, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013.
   PubMed Web of Science ®Google Scholar
• Moehler M LBA6_PR - Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study; 2020 Sep 21. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020
   Google Scholar
• Kato K LBA8_PR - Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study; 2020 Sep 21. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020
   Google Scholar
• Walk EE, Yohe SL, Beckman A, Schade A, Zutter MM, Pfeifer J, Berry AB. The Cancer Immunotherapy Biomarker Testing Landscape. Arch Pathol Lab Med. 2020;144(6):706–724. doi:10.5858/arpa.2018-0584-CP.
   PubMed Web of Science ®Google Scholar
• Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlen M, Mardinoglu A, Leandersson K, Jirström K. Expression of PD-L1 and PD-1 in chemoradiotherapy-naive esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival. Front Oncol. 2019;9:136. doi:10.3389/fonc.2019.00136.
   PubMed Web of Science ®Google Scholar
• Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7(17):24269–24283. doi:10.18632/oncotarget.8169.
   PubMed Web of Science ®Google Scholar
• Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, Zhong X, Li X, Qian H, Wang X, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One. 2017;12(8):e0182692. doi:10.1371/journal.pone.0182692.
   PubMed Web of Science ®Google Scholar
• Dislich B, Stein A, Seiler CA, Kroll D, Berezowska S, Zlobec I, Galvan J, Slotta-Huspenina J, Walch A, Langer R, et al. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases. Cancer Immunol Immunother. 2017;66(6):777–786. doi:10.1007/s00262-017-1982-2.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, et al. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018;7(6):e1435226. doi:10.1080/2162402X.2018.1435226.
   PubMed Web of Science ®Google Scholar
• Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, et al. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 2018;3(1):e000257. doi:10.1136/esmoopen-2017-000257.
   PubMed Web of Science ®Google Scholar
• Fukuoka E, Yamashita K, Tanaka T, Sawada R, Sugita Y, Arimoto A, Fujita M, Takiguchi G, Matsuda T, Oshikiri T, et al. Neoadjuvant chemotherapy increases PD-L1 expression and CD8 + tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Anticancer Res. 2019;39(8):4539–4548. doi:10.21873/anticanres.13631.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W, Zhong Q, Zhou A, Zeng Y. Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer. J Cancer. 2019;10(12):2754–2763. doi:10.7150/jca.31755.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez E, Gil GL, Benito AC, Gonzalez-Billalabeitia E, Conesa MA, Garcia Garcia T, García-Garre E, Vicente V, De La Peña FA. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488. doi:10.1186/s13058-014-0488-5.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells. Clin Cancer Res. 2008;14(8):2413–2420. doi:10.1158/1078-0432.CCR-07-4491.
   PubMed Web of Science ®Google Scholar
• Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA, Nelson BH, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–934. doi:10.1158/1078-0432.CCR-16-1433.
   PubMed Web of Science ®Google Scholar
• Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28(3):651–657. doi:10.1093/annonc/mdw625.
   PubMed Web of Science ®Google Scholar
• Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL, et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017;19(1):91. doi:10.1186/s13058-017-0884-8.
   PubMed Web of Science ®Google Scholar
• Borg D, Larsson AH, Hedner C, Nodin B, Johnsson A, Jirstrom K. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. J Transl Med. 2018;16(1):290. doi:10.1186/s12967-018-1668-3.
   PubMed Web of Science ®Google Scholar
• Hedner C, Borg D, Nodin B, Karnevi E, Jirstrom K, Eberhard J. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. J Clin Pathol. 2018;71(5):451–462. doi:10.1136/jclinpath-2017-204774.
   PubMed Web of Science ®Google Scholar
• Sobin L, Wittekind C. TNM classification of malignant tumours, 7th Edition. Wiley-Blackwell; 2009. http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1444332414.html.
   Google Scholar
• Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours, 8th Edition. 8th ed. Wiley-Blackwell; Bridgewater, NJ: 2017 January. p. 272.
   Google Scholar
• Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu -T-T, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–1355. doi:10.1002/cncr.20916.
   PubMed Web of Science ®Google Scholar
• Hedner C, Borg D, Nodin B, Karnevi E, Jirstrom K, Eberhard J, St-Pierre Y. Expression and prognostic significance of human epidermal growth factor receptors 1 and 3 in gastric and esophageal adenocarcinoma. PLoS One. 2016;11(2):e0148101. doi:10.1371/journal.pone.0148101.
   PubMed Web of Science ®Google Scholar
• Schoop H, Bregenzer A, Halske C, Behrens HM, Kruger S, Egberts JH, Röcken C. Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a therapy Naive Cohort. Transl Oncol. 2020;13(2):165–176. doi:10.1016/j.tranon.2019.11.004.
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. doi:10.1158/0008-5472.CAN-09-3690.
   PubMed Web of Science ®Google Scholar
• Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43–53. doi:10.1111/cas.13424.
   PubMed Web of Science ®Google Scholar
• Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22(10):2329–2334. doi:10.1158/1078-0432.CCR-16-0224.
   PubMed Web of Science ®Google Scholar
• Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65. doi:10.1186/1471-230X-9-65.
   PubMed Web of Science ®Google Scholar
• Wang B, Xu D, Yu X, Ding T, Rao H, Zhan Y, Zheng L, Li L. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol. 2011;18(9):2585–2593. doi:10.1245/s10434-011-1609-3.
   PubMed Web of Science ®Google Scholar
• Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, Oertli D. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol. 2010;36(7):670–677. doi:10.1016/j.ejso.2010.05.012.
   PubMed Web of Science ®Google Scholar
• Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85(1–2):50–63. doi:10.1159/000473881.
   PubMed Web of Science ®Google Scholar